Kidney Cancer

Off-Clamp Partial Nephrectomy Better for Preserving Renal Function

Off-Clamp Partial Nephrectomy Better for Preserving Renal Function

By

In a study, the off-clamp approach to partial nephrectomy also was associated with lower risk for acute kidney injury.

Biomarkers May Predict TKI Response in Metastatic RCC

Biomarkers May Predict TKI Response in Metastatic RCC

Circulating blood biomarkers related to angiogenesis may help clinicians predict who will have a robust response to sunitinib.

Certain Renal Cancer Subtypes Linked to Obesity

Certain Renal Cancer Subtypes Linked to Obesity

By

Obesity is associated with an increased likelihood of clear cell and possibly chromophobe renal cell carcinoma.

Renal Tumor Size Influences Its Aggressiveness

Renal Tumor Size Influences Its Aggressiveness

By

The likelihood of aggressive kidney tumor histology increased along with tumor size, a new study found.

Rise in Localized High-Risk RCC Reported

Rise in Localized High-Risk RCC Reported

By

Over a 25-year period, the proportion of patients with high-risk clinical T1 tumors increased by nearly 20% and clinical tumor size decreased from 8.4 to 6.2 cm, an Italian study found.

Robotic Partial Nephrectomy Mostly Superior to Other Surgeries

Robotic Partial Nephrectomy Mostly Superior to Other Surgeries

By

Robotic PN was associated with significantly lower rates of complications, cancer recurrence, and mortality compared with open and laparoscopic PN.

High Body Mass Index May Predict Survival Outcomes in RCC

High Body Mass Index May Predict Survival Outcomes in RCC

The association between obesity, age, and renal cell carcinoma prognosis requires additional investigation.

New Findings Support Ablation for Small Renal Tumors

New Findings Support Ablation for Small Renal Tumors

By

Percutaneous ablation offers cancer-related outcomes similar to those of radical nephrectomy but with a lower likelihood of long-term renal insufficiency and complications.

Cancer Development Linked to Increased Diabetes Risk

Cancer Development Linked to Increased Diabetes Risk

Increased risk of subsequent diabetes independent of traditional diabetes risk factors.

Robotics Involved in Most Urologic Cancer Surgeries

Robotics Involved in Most Urologic Cancer Surgeries

By

In 2015, 69% of surgeries for prostate, bladder, and kidney cancer were performed with robotic assistance, a new meta-analysis shows.

Sunitinib Alone or After Surgery for mRCC Offers Similar Outcomes

Sunitinib Alone or After Surgery for mRCC Offers Similar Outcomes

By

New findings from the CARMENA trial contradict previous research showing better survival from cytoreductive nephrectomy followed by targeted therapy.

Readmission Risk Factors for Radical Nephrectomy Patients Identified

Readmission Risk Factors for Radical Nephrectomy Patients Identified

By

Race, procedure and insurance type, sex, surgeon volume, and hospital size influence the risk of readmission among patients undergoing radical nephrectomy, study finds.

Partial vs Radical Nephrectomy Lowers Elderly Patient Mortality Risk

Partial vs Radical Nephrectomy Lowers Elderly Patient Mortality Risk

By

Study shows that partial nephrectomy for small renal tumors is associated with lower risk of cancer-specific and other-cause mortality in patients aged 75 years and older.

Diabetes Ups Kidney Cancer Risk in Women

Diabetes Ups Kidney Cancer Risk in Women

By

Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.

Smoking Ups Bladder Cancer Risk, Lowers Prostate Cancer Risk

Smoking Ups Bladder Cancer Risk, Lowers Prostate Cancer Risk

By

Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.

Odds of Prescribing Drugs Up With Doc Receipt of Payments

Odds of Prescribing Drugs Up With Doc Receipt of Payments

Doctors who receive general payment for cancer drug more likely to prescribe drug marketed by company.

Nivolumab plus ipilimumab improves survival in advanced renal cell carcinoma

1. Amongst patients with advanced renal-cell carcinoma and an intermediate or poor prognosis, nivolumab plus ipilimumab was superior to sunitinib alone in improving overall survival. 2. Though not statistically compared, there was a lower incidence of grade three or four adverse events with nivolumab plus ipilimumab, although more patients in the combination therapy arm stopped []

Relative Visceral Fat Indicates Mortality Risk for Women With RCC

Relative Visceral Fat Indicates Mortality Risk for Women With RCC

An evaluation of patients with clear cell renal cell carcinoma revealed greater risk of death for female patients with high relative visceral fat area (rVFA), highlighting the significance of metabolic differences between men and women.

Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors

Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors

Myocarditis with ICIs may be more common than initially thought; responds to higher steroid dosages

Older Age May Up Risk for RCC-Related Death After Surgery

Older Age May Up Risk for RCC-Related Death After Surgery

By

The risk of dying from pT1a renal cell carcinoma after partial or radical nephrectomy increases along with patient age.

Nivolumab Plus Ipilimumab Better for Advanced RCC

Nivolumab Plus Ipilimumab Better for Advanced RCC

By

Among intermediate- and poor-risk patients, the risk for death was 37% lower with nivolumab plus ipilimumab than with sunitinib.

Robotic PN May Offer Better Outcomes Than RFA for T1a RCC

Robotic PN May Offer Better Outcomes Than RFA for T1a RCC

By

Two-year recurrence-free survival was 100% vs 95.2% among robotic surgery and radiofrequency ablation patients, respectively.

Small Renal Masses Initially Grow at Variable Rates

Small Renal Masses Initially Grow at Variable Rates

Not reliable predictor of adverse outcomes in those under active surveillance; less variability over time

First-line Pazopanib May Improve Outcomes in Advanced RCC

First-line Pazopanib May Improve Outcomes in Advanced RCC

By

Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

By

The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

By

In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

By

Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

By

Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.

Urologic Cancer Surgery Readmission Rate Highest for RC

Urologic Cancer Surgery Readmission Rate Highest for RC

By

In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.

Jury Still Out on Whether Immunotherapy Can Cure Metastatic RCC

Jury Still Out on Whether Immunotherapy Can Cure Metastatic RCC

Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.

Sign Up for Free e-newsletters